. Almost all cell types release extracellular vesicles that are found in the plasma and other bodily fluids, including breast milk, semen, saliva, urine and sputum. Extracellular vesicles participate in important biological functions, acting as a mode of communication between cells. This intercellular communication can be conferred by mediators that are expressed on the surface of the extracellular vesicles or that are contained within the extracellular vesicle lumen.
Extracellular vesicles that are produced by both immune and non-immune cells have important roles in the regulation of immunity. They can mediate immune stimulation or suppression and they can drive inflammatory, autoimmune and infectious disease pathology. Thus, extracellular vesicles have the potential to be used as therapeutic agents to modulate the immune system. In this Review, we focus on the biology of the 30-100 nm extracellular vesicles known as exosomes and the mechanisms through which they regulate the immune response. Moreover, we discuss the potential application of these extracellular vesicles in the treatment of inflammatory and autoimmune diseases as well as cancer.
Biogenesis and trafficking of exosomes
Exosomes are generated by the inward budding of an endosomal membrane. The resulting invaginations are pinched off and released as intraluminal vesicles (ILVs) inside the endosomes, which are then termed MVBs
Tetraspanin
An evolutionarily conserved four transmembrane domain protein that associates with other tetraspanins, integrins, MHC molecules or signalling receptors in tetraspanin-enriched domains, and this leads to the regulation of multiple cell functions including cell adhesion, morphogenesis, proliferation, differentiation, synapse formation and tumour invasion.
MVBs fuse with the plasma membrane, which results in the release of ILVs as exosomes and the incorporation of the peripheral membrane of the MVBs into the plasma membrane. In the lysosomal pathway, MVBs fuse with lysosomes, releasing ILVs into the lysosomal lumen for degradation.
The generation of exosomes requires the sorting of the exosome-targeted proteins and lipids into the endosomal membrane, the delivery of the exosome cargo into nascent ILVs and the excision of ILVs. The monoubiquitylation of cytosolic domains of transmembrane proteins that have been internalized from the cell surface or transported from the trans-Golgi network functions as a sorting signal that directs proteins to ILVs (FIG. 1) . The ubiquitylated proteins are captured by the endosomal sorting complex for transport (ESCRT) machinery 7, 8 . However, MVBs can still be generated in the absence of key subunits of ESCRTs, which indicates the existence of alternative mechanisms of exosome biogenesis 9 . In addition, the sorting of certain proteins, such as MHC class II molecules, into ILVs is independent of ubiquitylation. Indeed, in oligodendrocytes, the sorting of proteolipid proteins into ILVs is ESCRT independent 10 (FIG. 1) ; instead, it requires segregation in sphingolipid-containing lipid rafts in the MVB membrane. Sphingomyelinases then break down the sphingolipids to release ceramide, which is thought to have a role in ILV budding 10 . Indeed, exosomes are enriched in sphingolipids, ceramide and the lipid raft component cholesterol 10 .
Stoorvogel and colleagues 11, 12 have suggested the existence of two pools of MVBs: one that is high in tetraspanin-enriched microdomains and associated lipids (cholesterol, sphingomyelin and ganglisode GM3), that is detergent-resistant, that is low in lysobisphosphatidic acid and that follows the exosome secretory pathway; and another that is low in cholesterol, high in lysobisphosphatidic acid and that is targeted to the lysosomal pathway. Indeed, these authors showed that in immature dendritic cells (DCs) MHC molecules are sorted into ILVs in MVBs and are targeted for lysosomal degradation, whereas in mature DCs MHC molecules are sorted into ILVs in MVBs that are enriched in the tetraspanin CD9 and are targeted for secretion 11, 12 . The mechanisms by which MVBs traffic to the cell periphery, fuse with the cell membrane and release their ILV cargo, require the coordinated action of the cytoskeleton, the molecular motors and the vesicle fusion machinery (FIG. 1) . Similarly to most intracellular transport pathways, MVB trafficking is controlled by the RAB family of small GTPases. Knock down of expression of RAB2B, RAB9A, RAB5A, RAB27A or RAB27B inhibits exosome secretion in tumour cells 13, 14 . RAB27A functions in the docking and the fusion of MVBs to the cell membrane, whereas RAB27B participates in the transfer of vesicles from the Golgi to MVBs and in the mobilization of MVBs to the actinrich cortex under the plasma membrane 13 . In the K562 erythroleukaemic cell line, RAB11 promotes the fusion of MVBs to the surface membrane in response to increased cytosolic calcium 15 . Although the mechanism by which this occurs is poorly characterized, the fusion of MVBs to the plasma membrane seems to depend on SNAP receptors (SNAREs), which are a superfamily of proteins that regulate the fusion and the target specificity in intracellular vesicle trafficking 16 . Once secreted, extracellular vesicles bind to neighbouring cells or to the extracellular matrix, or passively traffic through the bloodstream or through other bodily fluids. Certain blood-borne extracellular vesicles are rapidly captured by marginal zone phagocytes in the spleen, 23 . This idea received further support following the observation that the vaccination of mice with exosomes derived from tumour peptide-pulsed DCs primes tumour-specific cytotoxic T lymphocytes (CTLs) and suppresses tumour growth in a T cell-dependent manner 24 (see below). Following these observations, numerous studies have shown the direct effects of extracellular vesicles in T cell activation.
Extracellular vesicles maintain the topology of the antigen-presenting cell (APC) of origin, exposing the extracellular domain of MHC molecules at the vesicle surface. Extracellular vesicles that are released by APCs carry surface MHC class I and class II molecules and, therefore, potentially can directly stimulate CD8 + and CD4 + T cells, respectively. At fairly high concentrations, APC-derived extracellular vesicles that bear peptide-MHC complexes function as antigen-presenting vesicles for T cell clones, lines and hybrids, and for primed T cells 18, 19, 23, 25 . Similarly, extracellular vesicles that have been pulsed in vitro with peptides from Epstein-Barr virus (EBV), cytomegalovirus (CMV) and influenza virus have been shown to directly trigger interferon-γ (IFNγ) secretion by a small percentage of human peripheral CD8 + T cells, which are probably memory T cells 26 . However, the T cell stimulatory activity of free extracellular vesicles seems to be 10-20-fold less efficient than that of the parent APCs 21, 23 . This might explain the poor ability of free APC-derived extracellular vesicles to stimulate naive T cells in vitro 19, 27 -which require higher levels of TCR crosslinking and co-stimulation than T cell clones, T cell lines, activated T cells and memory T cells. The weak T cell stimulatory ability of free extracellular vesicles in vitro is probably also due to their small size and the vesicle dispersion that is caused by Brownian motion. Indeed, when APC-derived extracellular vesicles are immobilized at high concentration on latex beads, or when the number of peptide-MHC complexes per vesicle is enhanced by the direct loading of the vesicles with peptides, extracellular vesicles substantially increase their T cell stimulatory capacity in culture 21, 28, 29 .
Indirect antigen presentation through transfer of antigenic peptides to APCs. The capacity of free extracellular vesicles to stimulate T cells, including naive T cells, can be enhanced by the interaction of the vesicles with DCs 17, 21, 27, [30] [31] [32] [33] [34] . Real-time microscopy showed that extracellular vesicles that are attached to cells move in a slow drifted mode, which is similar to the motion of integral membrane proteins that are connected to the underlying cytoskeleton; this suggests that extracellular vesicles bind to surface receptors on target cells 35 . Indeed, extracellular vesicles have surface ligands that can bind to target cells 36, 37 or to extracellular matrix proteins 38, 39 . The presence of certain adhesion molecules that are involved in exosome binding to DCs 40 , such as integrins and intercellular adhesion molecule 1 (ICAM1; also known as CD54), depends on the lineage and the activation stage of the parent cells. Indeed, exosomes that are released by lipopolysaccharide-treated DCs (that is, mature exosomes) have more surface MHC class II, CD86 and ICAM1 molecules and have a greater T cellstimulatory capacity than exosomes that are secreted by immature DCs 17, 29, 31, 41 . The increased stimulatory function of mature DC-derived exosomes is at least partly due to their higher ICAM1 content, which could increase binding of the vesicles to APCs or could enhance T cell binding and/or activation during APC-T cell interactions. Indeed, DC-derived mature exosomes transfer the ability to activate naive T cells to non-professional APCs 31 . In addition, T cell activation induces a conformational change in the integrin lymphocyte functionassociated antigen 1 (LFA1; also known as β2 integrin and CD11a), which augments its affinity for ICAM1 on DC-derived exosomes 18 . Other ligands, including milk fat globule E8 (MFGE8; also known as lactadherin), tetraspanins and externalized phosphatidylserine, are constitutively present on extracellular vesicles. These ligands and adhesion molecules participate either directly or indirectly in the binding of extracellular vesicles to DCs 36, 37, 42 . For example, MFGE8, which is a secreted glycoprotein, binds to externalized phosphatidylserine on extracellular vesicles 1, 43 and can function as a bridge between the vesicles and the target cells by binding to αVβ3 or αVβ5 integrins on DCs and macrophages. However, extracellular vesicles that arise from MFGE8-deficient DCs can still transfer peptide-MHC complexes to DCs, which suggests that there is redundancy in the mechanisms by which extracellular vesicles bind to DCs 44 . Phosphatidylserine is also recognized by T cell immunoglobulin mucin receptor 1 (TIM1; also known as HAVCR1) and TIM4 on target leukocytes 45, 46 . Carbohydrates on the vesicle surface also participate in the recognition and the uptake of the vesicles by phagocytes. The lectin galectin 5 impairs the uptake of reticulocyte-derived exosomes by macrophages by binding to β-galactosides on the vesicles and thereby inhibiting their recognition by macrophage lectin receptors 47 . A proportion of the acquired extracellular vesicles remains on the surface of the target cell, whereas the rest are internalized by phagocytosis or macropinocytosis 17 vesicles more efficiently than mature DCs, whereas mature DCs retain more extracellular vesicles on the cell surface 17 . Once exosomes are internalized by DCs, the exosome-borne peptide-MHC complexes can be degraded by the APCs and can be used as a source of peptides to indirectly interact with T cells 17, 32 (FIG. 2) .
For example, exosomes that are released by human intestinal epithelial cells and that bear the MHC class II molecule HLA-DR4 loaded with the human serum albumin peptide only activate specific T cell hybrids in the presence of HLA-DR4 + DCs, which suggests that the extracellular vesicles transfer the peptide from their HLA-DR4 molecules to HLA-DR4 molecules on the DCs 32 . Similar results have been reported in vivo: extracellular vesicles that carry the mouse MHC class II molecule IA b loaded with an allopeptide (from MHC class II IE α-chain) triggered the proliferation of specific CD4 + T cells in wild-type mice, but not in MHC class-II-deficient hosts 17 .
Indirect antigen presentation by cross-dressing APCs.
Peptide-MHC complexes of extracellular vesicles that are attached (or fused) to APC surfaces can also be directly presented to T cells without the need for peptide-MHC reprocessing -through a mechanism known as cross-dressing (FIG. 2) . The finding that optimal T cell stimulation occurs when exosomes transfer peptide-MHC complexes to mature DCs indicates that the acceptor APCs provide the required co-stimulatory molecules that are absent in the extracellular vesicles 17, 27, 40 . . However, the maximal T cell stimulation that was triggered by extracellular vesicles in the presence of MHC class II-deficient DCs was less than that elicited in the presence of wild-type DCs, which suggests that part of the T cell response is triggered by the indirect presentation of the exosome-carried peptide by DC-derived IA b molecules 27 . Finally, there are several lines of evidence suggesting that, following allograft transplantation, the cross-dressing of the recipient's APCs with donor MHC molecules could be mediated through exosome transfer 50 . By contrast, exosomes do not seem to participate in the cross-dressing of APCs during the priming of T cells after viral infections 34, 51 .
Extracellular vesicles as carriers of antigens
Tumour antigens. Extracellular vesicles also transfer native antigens to APCs. Tumour-derived extracellular vesicles containing native tumour antigens can be efficiently taken up by DCs for antigen processing and cross-presentation to tumour-specific CTLs 52, 53 (FIG. 3) .
Moreover, vaccination of mice with tumour-derived exosomes was shown to induce a potent CD8 + T cellmediated antitumour effect not only on the autologous tumour but also against other related tumours that express the same tumour rejection antigen or antigens 52 . Importantly, vaccination of mice with syngeneic or allogeneic tumour-derived extracellular vesicles is equally effective, as cross-protection against tumours is mediated by the processing of exosome-derived tumour antigens by host DCs, which is independent of the MHC molecules of the donor extracellular vesicles 52 . Indeed, human tumour exosomes bearing the MART1 tumour antigen and a mismatched HLA haplotype promoted the activation of an HLA-A2-restricted CTL clone that was specific for MART1 when extracellular vesicles were taken up by HLA-A2 + DCs 53 . The possibility that tumour extracellular vesicles efficiently deliver unknown tumour antigens to DCs for CTL cross-priming makes exosomebased vaccines an attractive prophylactic or therapeutic approach against cancer.
Pathogenic antigens. Certain microbial components can also be present in extracellular vesicles (FIG. 3) . Macrophages infected with Mycobacterium bovis bacillus Calmette-Guérin release extracellular vesicles that contain mycobacterial antigens that, in the presence of 
Cross-presentation
The transfer of biosynthesized antigen in a complex form (for example, as apoptotic cell fragments or associated with heat shock protein) from donor (infected or tumour) cells to the cytosol of acceptor antigen-presenting cells for processing and presentation through MHC class I molecules to CD8 + T cells. In certain cases, the acquired antigen can be presented by MHC class I molecules through a transporter associated with antigen processing (TAP)-independent mechanism that involves delivery of the antigen to MHC class I-containing phagolysosomes.
DCs, promote T cell immunity in mice 33 . Furthermore, vaccination with extracellular vesicles that have been released by Toxoplasma gondii-pulsed DCs confers protection against parasite infection in mice, which suggests that the extracellular vesicles transport toxoplasma antigens 54 . Certain viral antigens are also targeted into the exosome pathway. the oncogenic viral antigen latent membrane protein 1 (LMP1) 56 . Influenza virus haemagglutinin, because of its localization in raft domains, is sorted into the exosome membrane with its extracellular domain facing outwards 57 . This incorporation of haemagglutinin increases the ability of the extracellular vesicles to bind to acceptor cells through terminal sialic acid residues 57 . As exosomes originate in MVBs that are positioned along the endocytic route, they can transport antigens that are internalized by the parent cells, which could be important for their therapeutic applications 58 (FIG. 3; see Supplementary information S1 (table)). Alternatively, by genetically engineering the parent cells, antigens that are not naturally present on extracellular vesicles could be delivered into the vesicles [59] [60] [61] . Given their high immunogenic potential, antigen-associated extracellular vesicles that are released by antigen-pulsed or genetically-engineered parent cells constitute a promising cell-free system for vaccination, particularly for peptides that are present at low frequency or that are weakly immunogenic 59 . BCR antigens. B cells recognize conformational epitopes on native antigens, which are presented as immune complexes on follicular DCs (FDCs) within B cell follicles 62 . The immune complexes activate the complement system, leading to the generation of iC3b, C3dg and C3d fragments, which bind to complement receptor type 1 (CR1; also known as CD35) and CR2 (also known as CD21) on FDCs. Multiple copies of native antigens arranged at regular intervals, together with iC3b, C3dg and C3d, are presented to B cells on FDC-derived iccosomes, which promote B cell receptor (BCR) crosslinking and CR2-mediated B cell activation, respectively. Increasing evidence suggests that extracellular vesicles that are attached to FDCs could use similar mechanisms to promote B cell immunity.
FDCs do not synthesize MHC class II molecules, but they can acquire peptide-MHC class II complexes by capturing MHC class II + extracellular vesicles that are probably released by follicular B cells 63 . Since FDCs are non-phagocytic, the captured extracellular vesicles might remain on the cell surface for a long time. Interestingly, FDCs synthesize MFGE8 and express ICAM1, CR1 and CR2, which could participate in the docking or the binding of extracellular vesicles through ligation to phosphatidylserine, CD11a and/or C3-derived fragments 62, 64 . Indeed, B cells release extracellular vesicles bearing C3-derived fragments as a mechanism of elimination of C3 fragments that are deposited on the cell membrane in physiological conditions 65 . Exosomes are protected from complement lysis because they have the complement regulatory proteins CD55 and CD59 on their surface, which inhibit C3b deposition and the assembly of the membrane attack complex, respectively 66 . After the immunization of mice with exosomes from DCs that were loaded with ovalbumin (OVA), the generation of T cell immunity was shown to require antigen-specific B cell assistance 29 . As B cells recognize conformational epitopes, this finding suggests that, to be effective immunogens, extracellular vesicles must carry B cell epitopes as native or partially-degraded antigens 29 . Resting B cells release extracellular vesicles after stimulation with IgM-specific antibodies and CD40 signalling 19 , which are conditions that mimic the activation of B cells by FDCs in vivo 62 . Extracellular vesicles released by B cells undergoing activation express MHC molecules that are loaded with peptides derived from the internalized native antigens. Therefore, it is likely that at the FDC surface extracellular vesicles bearing copies of native antigens stimulate antigen-specific B cells and extracellular vesicles carrying peptide-MHC class II complexes (which are released by follicular B cells undergoing activation) attract and/or stimulate follicular helper T cells that are specific for that particular peptide-MHC complex. This scenario would lead to an antigen-specific B cell-T cell interaction and to the development of B cell immunity. B cells also augment the release of exosomes following cognate interactions with CD4 + T cells 19, 67 . At later stages of B cell differentiation, ex vivo experiments suggest that, following stimulation, allergen-specific B cells release exosomes that activate T helper 2 cells 25 .
Extracellular vesicles in the transfer of RNAs
As well as being carriers of protein antigens, extracellular vesicles constitute a mechanism for the intercellular passage of genetic information in the form of RNAs, which suggests that tissue-targeted extracellular vesicles could be potential delivery platforms for gene therapy (see below) 2, 60, 68 . Extracellular vesicles that are secreted by normal or cancer cells have been found to contain functional mRNAs and small ncRNAs, including miRNAs [69] [70] [71] [72] [73] [74] [75] [76] , but generally not DNA (with the exception of amplified MYC extra-chromosomal DNA that is found in certain tumour-derived extracellular vesicles 6 ) or ribosomal RNAs 70 . The RNAs that are transported by extracellular vesicles are protected from degradation by RNases 70 . Some mRNAs and miRNAs are detected in both extracellular vesicles and parent cells, whereas others are identified in either extracellular vesicles or in parent cells, which suggests a preferential sorting of certain RNA sequences into extracellular vesicles 70, 77 . The passage of RNAs from the lumen of the extracellular vesicles into the target cells requires the release of the vesicle contents into acceptor cells (FIG. 4) . This involves the docking of extracellular vesicles on target cells (predominantly at cholesterol-rich microdomains) and the fusion of their membranes, as shown by incubating DCs with extracellular vesicles that have been labelled with a lipophilic probe 78, 79 . The delivery of exosome contents into the cytosol of target cells has been shown by content-mixing assays, in which DCs that express transgenic luciferase in the cytoplasm were incubated with luciferin-loaded extracellular vesicles 78 . The finding that the miRNAs miR-148a and miR-451 that are delivered by DC-derived exosomes are functional in miRNA reporter assays in acceptor DCs suggests that this phenomenon is a means of horizontal propagation of post-transcriptional regulation among (FIG. 4) . Indeed, antigen-induced assembly of the immunological synapse triggers the polarization of T cell MVBs to the point of APC-T cell contact, and promotes the transfer of exosomal miR-335, which is functional in miRNA reporter assays in acceptor APCs 77 . EBVinfected B cells transfer exosome-derived viral miRNAs to DCs, which silences mRNA transcripts that encode immune-stimulatory molecules 80 .
Activation of immunity by extracellular vesicles
Increasing evidence suggests that extracellular vesicles transfer not only antigens to APCs but also signals that may promote the activation of the acceptor cells into immunogenic APCs. Mast cell-derived extracellular vesicles, which contain a relatively high content of heat shock protein 60 (HSP60) and HSPA8 (also known as HSC70), promote DC maturation in mice 58 . Macrophages that have been infected with Mycobacterium tuberculosis, Salmonella enterica subsp. enterica serovar Typhimurium or T. gondii release extracellular vesicles that carry microbial antigens, as well as pathogen-associated molecular patterns that promote a Toll-like receptor-dependent inflammatory response by macrophages 81 . This adjuvant-intrinsic effect, together with the vesicular nature of extracellular vesicles, may explain why extracellular vesicles are more efficient than soluble peptides at transferring antigens between APCs.
Interleukin-1β (IL-1β), which is a cytokine that lacks the leader sequence needed for secretion by the classical pathway, is released inside the extracellular vesicles secreted by DCs and macrophages [82] [83] [84] . How IL-1β is then released from the vesicle lumen remains unknown.
Unlike IL-1β, other cytokines are transported on the extracellular vesicle surface. Tumour necrosis factor (TNF) superfamily members, including CD95 ligand (CD95L; also known as FASL), TNF-related apoptosis-inducing ligand (TRAIL; also known as TNFSF10) and CD40 ligand (CD40L; also known as CD154), are sorted into the exosome membrane. CTLs, natural killer (NK) cells and DCs kill target cells through the polarized release of CD95L-carrying extracellular vesicles [85] [86] [87] [88] . Tumour cells and parenchymal cells of immune-privileged tissues also secrete CD95L via extracellular vesicles as a mechanism of immune escape 89, 90 . In addition, mast cells release CD40L-bearing extracellular vesicles 91 and platelets secrete vesicles that deliver CD40L-CD40 signalling 92 . The release of TNF superfamily molecules through extracellular vesicles decreases the degradation of these molecules by surface proteases, augments their local concentration in the extracellular milieu and favours their aggregation into trimers, thereby increasing their biological activity 87 . DC-derived and macrophage-derived exosomes carry enzymes that synthesize leukotriene B4 (LTB4) and LTC4 (REF. 93 ). At sites of inflammation, unstable LTA4 that is released by neutrophils could be converted into pro-inflammatory LTB4 and LTC4 by APC-derived extracellular vesicles.
In addition, extracellular vesicles seem to have a role in mediating inflammatory and autoimmune diseases; for example, extracellular vesicles in the serum and that are derived from the synovial fibroblasts of patients with rheumatoid arthritis have higher levels of a membrane-bound form of TNF -which is a key target in the treatment of rheumatoid arthritis -than extracellular vesicles from healthy control individuals 94 . Interestingly, these TNF-positive extracellular vesicles Delayed-type hypersensitivity response (DTH response). A CD4 + T cell-driven, antigen-specific immune response that is induced by intradermal antigen immunization followed by injection of the antigen in the skin of the ear or the footpad. The immune response is measured by swelling and redness.
Myeloid-derived suppressor cells (MDSCs) . A heterogeneous population of leukocytes of myeloid lineage that increase in number during cancer and inflammation and that suppress T cell responses. They include myeloid progenitor cells, immature macrophages, granulocytes and dendritic cells.
render activated T cells resistant to apoptosis, which could contribute to the T cell-mediated pathogenesis of rheumatoid arthritis. In addition, citrullinated proteins and the nuclear protein DEK, which are known to be autoantigens in rheumatoid arthritis, were detected in extracellular vesicles that were purified from the synovial fluid of patients with rheumatoid arthritis and juvenile arthritis, respectively 95 . In addition, extracellular vesicles that are found in the articular cartilage of patients with osteoarthritis mediate mineral formation and the destruction of articular cartilage 96 .
Immunosuppression by extracellular vesicles Tolerosomes. Besides their obvious roles in promoting immune responses, endogenous extracellular vesicles have also been shown to have immunosuppressive effects following antigen immunization through certain routes and in tumour models. Oral administration of OVA resulted in the generation of MHC class II + vesicles in the serum that could suppress OVA-specific immune responses and were therefore termed tolerosomes 97 . These MHC class II + circulating vesicles seem to be derived from intestinal epithelial cells that acquire antigens after oral administration 97 . Similarly, following intradermal immunization with OVA, extracellular vesicles that suppress an OVAspecific delayed-type hypersensitivity response (DTH response) in the footpad could be isolated from the plasma 98 . The OVA-specific, circulating suppressive extracellular vesicles were MHC class II + and required both MHC class I and CD95L for their suppressive effects. Interestingly, the number and/or the activity of the OVA-specific immunosuppressive extracellular vesicles in the blood peaked 14 days post immunization. Thus, it has been hypothesized that the functional relevance of blood-borne extracellular vesicles is to reduce an active immune response to an antigen that has been encountered through certain immunization routes 98 and that they may suppress responses to peripheral self antigens and to commonly encountered foreign antigens to inhibit chronic inflammation and autoimmunity. Exosomes isolated from the bronchoalveolar fluid of mice that were previously tolerized to the pollen allergen Ole e 1 by repetitive intranasal inoculation prevented allergic reactions against Ole e 1 in a mouse model, which suggests that bodily fluids other than the blood also contain antigen-specific immunosuppressive extracellular vesicles 99 .
Tumour-derived extracellular vesicles. Tumour-derived extracellular vesicles have been reported both to stimulate and to suppress tumour-specific and nonspecific immune responses. Given that the protein composition of extracellular vesicles is similar to the parental cell type, tumour-derived extracellular vesicles contain tumour-specific antigens. In fact, certain tumourderived extracellular vesicles are enriched for tumour antigens such as melan A, carcinoembryonic antigen (CEA) and mesothelin compared with the parental tumour cells 52,53,100 . Therefore, tumour-derived extracellular vesicles have been used as a source of tumour antigens to stimulate an antitumour response (see below). However, despite this, there is substantial evidence that suggests that tumour-derived extracellular vesicles primarily suppress antigen-specific and nonspecific antitumour responses; for example, tumour-derived extracellular vesicles are enriched for CD95L, TRAIL or galectin 9, which can promote T cell apoptosis 89, 101, 102 . Moreover, tumour-derived extracellular vesicles suppress CD3 ζ-chain expression by T cells and block NK group 2 member D (NKG2D)-dependent cytotoxicity of NK cells and CD8 + T cells 103 . In addition, tumour-derived extracellular vesicles have numerous effects on APC function; for example, monocyte differentiation can be altered to favour the generation of myeloid-derived suppressor cells (MDSCs), through the presence of prostaglandin E2 (PGE2), transforming growth factor-β (TGFβ), HSP72 and miRNAs in tumour-derived vesicles [104] [105] [106] [107] . MDSCs in turn induce or support the function of regulatory T (T Reg ) cells, which inhibit antitumour responses. In addition, tumourderived extracellular vesicles can directly affect T Reg cells, both by enhancing their function and by inhibiting their apoptosis. Tumour-derived extracellular vesicles can also block the maturation of DCs and macrophages in vivo and in vitro through a TGFβ1-dependent mechanism 108 . An example of antigen-specific immune suppression by tumour-derived extracellular vesicles has been shown using OVA as a model tumour antigen. Extracellular vesicles that were derived from an OVAexpressing melanoma and that contained the fulllength OVA protein were shown to effectively suppress an OVA-specific immune response 109 . In addition, in tumour-bearing mice, blood-borne extracellular vesicles that were positive for CD11b were shown to suppress tumour antigen-specific responses through an MHC class II-dependent mechanism 110 . These observations suggest that tumour-derived extracellular vesicles initially modulate the function of CD11b + APCs in the tumour microenvironment, which in turn release immunosuppressive MHC class II + CD11b + vesicles into the circulation. How these endogenous vesicles suppress tumour antigen-specific responses is unclear, but they probably have an important role in tumour immune escape.
Although tumour-derived extracellular vesicles can suppress tumour-specific immune responses, vesicles also have a role in facilitating tumour invasion and metastasis. Tumour-derived extracellular vesicles have been shown to help to establish the premetastatic niche through the generation of a suitable microenvironment in distant metastatic sites 14, [111] [112] [113] [114] . In addition, melanoma-derived extracellular vesicles that have been injected in peripheral tissues preferentially home to sentinel lymph nodes to prepare lymph nodes to become remote niches for metastatic tumour growth 14 . Taken together, it seems that tumour-derived extracellular vesicles have important roles at multiple stages of tumour pathogenesis, from suppressing the antitumour responses to facilitating the formation of the metastatic niche. Immunosuppression by stem cell-derived extracellular vesicles. Adult stem cells, including mesenchymal stem cells (MSCs), from different sources confer regenerative effects in animal models of disease and tissue injury and are in Phase I and II trials for disorders including limb ischaemia, congestive heart failure and acute myocardial infarction 115 . In addition, MSCs confer immunosuppressive effects and have shown promise in clinical trials for Crohn's disease and graft-versus-host disease. However, in many of the cases where therapeutic effects have been observed using MSCs, the transplanted stem cells have not been documented to persist following injection or to contribute to tissue regeneration 116, 117 . Therefore, it is likely that the main immunosuppressive effects of adult stem cells result from paracrine mechanisms mediated by secreted factors, including extracellular vesicles. Indeed, in certain cases, injection of conditioned media from MSC cultures has been confirmed to suppress inflammation as efficiently as injection of the stem cells themselves [118] [119] [120] [121] [122] [123] . MSCs express several T cell-attracting chemokines, as well as immunosuppressive factors, such as indoleamine 2,3-dioxygenase (IDO), TGFβ1, PGE2 and IL-10 (REF. 118 ). Interestingly, analysis in animal models of inflammation suggests that MSC-derived vesicles are also immunosuppressive, probably through the transfer of RNAs and proteins carried by the extracellular vesicles 123, 124 . Thus, extracellular vesicles that are released from MSCs could be easily and safely administered for the treatment of autoimmune and inflammatory diseases, and possibly for tissue regeneration. Indeed, clinical studies have been initiated to treat graft-versus-host disease with MSC-derived extracellular vesicles.
Therapeutic uses of extracellular vesicles APC-derived extracellular vesicles. The ability of extracellular vesicles, especially those derived from APCs, to regulate the immune response can be enhanced through both pharmacological and biological treatments, including gene transfer of APCs. APCs, particularly DCs, can both positively and negatively regulate antigenspecific and nonspecific immune responses (FIG. 3; see Supplementary information S1 (table) ). This differential immune regulation partly depends on the level of expression of MHC molecules and co-stimulatory molecules (such as CD80 and CD86) and co-regulatory molecules (such as programmed cell death 1 ligand 1 (PDL1) and PDL2) 125 . Immature DCs express a low ratio of co-stimulatory molecules to co-regulatory molecules on their surface and are therefore immunosuppressive. Treatment of in vitro-generated DCs with immunosuppressive drugs or cytokines or genetically modifying them to express immunosuppressive agents renders the DCs immunosuppressive; for example, treatment of bone marrow-derived DCs with IL-10 or IL-4 resulted in DCs that could suppress established collagen-induced arthritis (CIA) and that could prevent the onset of hyperglycaemia in non-obese diabetic mice [126] [127] [128] [129] . Interestingly, treatment with extracellular vesicles that are derived from these in vitro-generated immunosuppressive DCs also reversed early onset CIA as effectively as, or more effectively than, the parental cells [129] [130] [131] [132] . Although the mechanisms of immunosuppression have not been completely elucidated, the suppressive DC-derived extracellular vesicles were internalized in vivo by DCs and macrophages of the spleen, liver and draining lymph nodes, and might then modify the behaviour of these cells to confer a systemic suppressive effect. The fact that injected extracellular vesicles are rapidly cleared by phagocytic leukocytes probably increases the therapeutic efficacy of this approach. Of note, the suppressive activity of the extracellular vesicles was MHC class II dependent, as extracellular vesicles from MHC class II-deficient DCs had no suppressive activity, whereas MHC class I-deficient extracellular vesicles retained their function 131 . Interestingly, the suppressive effect was also dependent on the presence of CD95 in the host mice and CD95L in the extracellular vesicles 131 . However, no change in the level of T cell apoptosis was observed following the injection of extracellular vesicles, which suggests a different mechanism of action from that of the CD95-CD95L pathway.
Immunosuppressive exosomes have also been used in transplantation. Donor-specific allograft immunosuppression was induced by co-treatment with donor DC-derived exosomes and a drug that blocks the maturation of recipient DCs 133 . Similarly, treatment of recipient mice with exosomes released by immature donor DCs, combined with a suboptimal dose of rapamycin before and after the transplant, markedly prolonged the survival of cardiac allografts in a mouse model 134 . The therapeutic effects of APCs and particularly APC-derived extracellular vesicles can also be efficiently enhanced by gene transfer. In this situation, APCs can be modified by nonviral methods, including liposomes, and virus-mediated gene transfer, including lentiviral and adenoviral vectors. The transfer of genes encoding immunoregulatory cytokines such as IL-4, IL-10 or TGFβ1 was shown to result in the release of APC-derived extracellular vesicles that are as immunosuppressive as the parent APCs. It is possible that the genetic modification results in the generation of APCs and extracellular vesicles that are more immunosuppressive. Alternatively, it is possible that a low level of cytokines contained within the vesicles contributes to the suppressive effects. Similarly, gene transfer of IDO to APCs resulted in the release of immunosuppressive extracellular vesicles 132 . Although IDO expression could be detected in the APC-derived extracellular vesicles, treatment of the genetically modified APCs with an IDO inhibitor reduced the suppressive effects of the extracellular vesicles 132 . This suggests that it is the activity of IDO in the APCs that renders the extracellular vesicles immunosuppressive, but the mechanism is unclear. In addition, gene transfer of CD95L to APCs results in the generation of highly immunosuppressive vesicles. In this context, the presence of exogenously expressed CD95L on the surface of the vesicles is required for immunosuppression 131 . Similar approaches could be used to genetically modify MSCs to render the MSC-derived extracellular vesicles more immunosuppressive.
Naturally-occurring immunosuppressive extracellular vesicles. In addition to extracellular vesicles that are derived from immunosuppressive APCs, there are naturally occurring immunosuppressive extracellular vesicles that could be therapeutically used. Autologous extracellular vesicles that have been isolated from plasma shortly after oral administration of antigen or following antigen inoculation could be used to induce antigen-specific immunosuppression 97, 98 . In addition, extracellular vesicles that have been isolated from the bronchoalveolar lavage fluid following exposure to specific antigens could be used to prevent antigenspecific allergic reactions 99, 135 . Similarly, extracellular vesicles that are present in human breast milk and colostrum and that can increase the number of T Reg cells could be used to suppress immune responses 136, 137 . Finally, pregnancy has been shown to alleviate the severity of rheumatoid arthritis and multiple sclerosis; thus, trophoblast cell-derived extracellular vesicles present in the maternal peripheral circulation could be used to inhibit T cell signalling 138 . The isolation and enrichment of these different types of autologous or allogeneic vesicle have clinical applications for the control of autoimmunity, alloimmunity and inflammatory diseases. Indeed, blood-based therapeutics such as platelet rich plasma (PRP) are already routinely used. In an unblinded clinical study, extracellular vesicles from a blood-based therapeutic treatment similar to using PRP showed evidence of efficacy in patients with severe rheumatoid arthritis, which shows the feasibility of therapeutically using autologous extracellular vesicles.
Enhancing immunostimulation by tumour-derived extracellular vesicles. Although tumour-derived extracellular vesicles seem to be predominantly immunosuppressive, they clearly are a source of tumour antigens. APCs that have been pulsed with extracellular vesicles derived from tumour cells cross-present the antigens to antigen-specific CTLs. The ability of APCs that have been treated with tumour-derived extracellular vesicles to stimulate T cell responses has resulted in the initiation of several clinical trials and the generation of some evidence of immunostimulation 139, 140 . In a clinical trial for malignant glioma, tumour exosomeloaded DCs were shown to stimulate a tumour-specific CTL response against autologous tumour cells 141 . However, generally the antitumour efficacy observed in these clinical studies has been limited, probably because of the need to render the tumour-derived extracellular vesicles or the DCs that are treated with tumour-derived extracellular vesicles more immunostimulatory. Enhancing immunostimulatory capacity could be achieved through different approaches including the treatment of the DCs with IFNγ 142 and the transfer of genes for cytokines, such as IL-12 and IL-2 (REFS 143,144), membrane-bound tumour antigens or HSPs 59, [145] [146] [147] . In addition, heat shocking tumour cells resulted in the release of extracellular vesicles that contain DC-and T cell-attracting chemokines 146 -a process that could be further enhanced by genetically modifying the tumour cells. Similar approaches could also be used to elicit immune responses to viral and bacterial antigens.
Several miRNAs and other ncRNAs that are present in extracellular vesicles probably contribute to the biological effects of these vesicles 2 . The ability to alter the RNA composition of the vesicles either by transfering a specific gene or ncRNA to the parent cell or by directly delivering miRNAs or small interfering RNAs (siRNAs) to the vesicle enables vesicles to be used as carriers of therapeutic RNAs. The feasibility of this approach has been shown using tumour-derived extracellular vesicles to deliver a therapeutic siRNA, but, in theory, this approach could be applied to a variety of extracellular vesicles 68 .
Concluding remarks
Most, if not all, cells release extracellular vesicles containing mRNAs, miRNAs, ncRNAs, proteins, lipids, carbohydrates and even metabolites. Thus, extracellular vesicles, which are similar in several aspects to enveloped viral particles, concentrate, transport and deliver molecules that function in important biological processes. Extracellular vesicles from both immune and non-immune cells positively and negatively modulate the immune response. In addition to the role of extracellular vesicles in the regulation of the immune response, it is likely that extracellular vesicles participate in age-related tissue degeneration, in the modulation of microbial infection, in autoimmune and inflammatory disease pathology, and in tumour initiation and progression. However, it is important to note that, although extracellular vesicles have been shown to exert effects on leukocytes in vitro or on innate and adaptive immune cells following the injection of purified extracellular vesicles that have been released by cells in culture, very little is known about the immunoregulatory role of these vesicles in vivo. There are only a few examples in which the effect of inhibiting the secretion of extracellular vesicles from a certain cell type has been examined in vivo 148 . Understanding how the extracellular vesicles from different immune cell types function to regulate immunity should result in the development of new therapeutic approaches; for example, inhibiting tumour-derived exosome function should result in reduced metastasis and a better antitumour immune response. Alternatively, it could be possible to deplete extracellular vesicles from the blood of cancer patients by apheresis. By contrast, modifying APC or MSC function in vivo or in vitro to facilitate the release of extracellular vesicles that are more immunosuppressive could be used to treat autoimmune disease, inflammatory disorders and graft-versus-host disease, as well as to facilitate transplantation. The feasibility and the safety of clinically using extracellular vesicles has been shown in several clinical studies using autologous, blood-derived or MSC-derived extracellular vesicles. Clearly, extracellular vesicles are important mediators and regulators of immunity for which there are and will be widespread therapeutic applications.
